Indication
Renal osteodystrophy with hyperphosphatemia
Renal osteodystrophy with hyperphosphatemia describes a complex metabolic bone disorder occurring in patients with advanced chronic kidney disease or end-stage renal disease, marked by concurrently elevated serum phosphorus levels. Read more about Renal osteodystrophy with hyperphosphatemia
82 drugs 53 manufacturers
Drugs that treat it
Common Renal osteodystrophy with hyperphosphatemia therapies.
CALCIUM ACETATE
CALCIUM ACETATE
AURYXIA (ferric citrate)
FOSRENOL (lanthanum carbonate)
CALCIUM ACETATE
CALCIUM ACETATE
CALCIUM ACETATE
CALCIUM ACETATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonRenal osteodystrophy with hyperphosphatemia describes a complex metabolic bone disorder occurring in patients with advanced chronic kidney disease or end-stage renal disease, marked by concurrently elevated serum phosphorus levels.
It primarily affects the skeletal and mineral endocrine systems as a consequence of impaired glomerular filtration and inadequate urinary phosphate excretion.
The resulting phosphate retention, coupled with deficient renal production of calcitriol and secondary hypocalcemia, triggers secondary hyperparathyroidism and elevated fibroblast growth factor 23.
This pathophysiologic cascade leads to aberrant bone remodeling—ranging from high-turnover osteitis fibrosa cystica to adynamic bone disease and osteomalacia—and markedly increases the risks of bone pain, pathologic fractures, and extraosseous calcification.
- nih.gov
Renal osteodystrophy with hyperphosphatemia describes a complex metabolic bone disorder occurring in patients with advanced chronic kidney disease or end-stage renal disease, marked by concurrently elevated serum phosphorus levels This pathophysiologic cascade leads to aberrant bone remodeling—ranging from high-turnover osteitis fibrosa cystica to adynamic bone disease and osteomalacia—and markedly increases the risks of bone pain, pathologic fractures, and extraosseous calcification
- orthobullets.com
Renal osteodystrophy with hyperphosphatemia describes a complex metabolic bone disorder occurring in patients with advanced chronic kidney disease or end-stage renal disease, marked by concurrently elevated serum phosphorus levels It primarily affects the skeletal and mineral endocrine systems as a consequence of impaired glomerular filtration and inadequate urinary phosphate excretion This pathophysiologic cascade leads to aberrant bone remodeling—ranging from high-turnover osteitis fibrosa cys...
- fpnotebook.com
It primarily affects the skeletal and mineral endocrine systems as a consequence of impaired glomerular filtration and inadequate urinary phosphate excretion The resulting phosphate retention, coupled with deficient renal production of calcitriol and secondary hypocalcemia, triggers secondary hyperparathyroidism and elevated fibroblast growth factor 23 This pathophysiologic cascade leads to aberrant bone remodeling—ranging from high-turnover osteitis fibrosa cystica to adynamic bone disease and ...
- wikipedia.org
The resulting phosphate retention, coupled with deficient renal production of calcitriol and secondary hypocalcemia, triggers secondary hyperparathyroidism and elevated fibroblast growth factor 23
Personalize your experience
Follow Renal osteodystrophy with hyperphosphatemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.